| Year |
Citation |
Score |
| 2023 |
Kaku K, Ravindra MP, Tong N, Choudhary S, Li X, Yu J, Karim M, Brzezinski M, O'Connor C, Hou Z, Matherly LH, Gangjee A. Discovery of Tumor-Targeted 6-Methyl Substituted Pemetrexed and Related Antifolates with Selective Loss of RFC Transport. Acs Medicinal Chemistry Letters. 14: 1682-1691. PMID 38116433 DOI: 10.1021/acsmedchemlett.3c00326 |
0.328 |
|
| 2023 |
Tong N, Wong-Roushar J, Wallace-Povirk A, Shah Y, Nyman MC, Katinas JM, Schneider M, O'Connor C, Bao X, Kim S, Li J, Hou Z, Matherly LH, Dann CE, Gangjee A. Multitargeted 6-Substituted Thieno[2,3-]pyrimidines as Folate Receptor-Selective Anticancer Agents that Inhibit Cytosolic and Mitochondrial One-Carbon Metabolism. Acs Pharmacology & Translational Science. 6: 748-770. PMID 37200803 DOI: 10.1021/acsptsci.3c00020 |
0.341 |
|
| 2022 |
Hou Z, Gangjee A, Matherly LH. The evolving biology of the proton-coupled folate transporter: New insights into regulation, structure, and mechanism. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 36: e22164. PMID 35061292 DOI: 10.1096/fj.202101704R |
0.318 |
|
| 2021 |
Wallace-Povirk A, Tong N, Wong-Roushar J, O'Connor C, Zhou X, Hou Z, Bao X, Garcia GE, Li J, Kim S, Dann CE, Matherly LH, Gangjee A. Discovery of 6-substituted thieno[2,3-d]pyrimidine analogs as dual inhibitors of glycinamide ribonucleotide formyltransferase and 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase in de novo purine nucleotide biosynthesis in folate receptor expressing human tumors. Bioorganic & Medicinal Chemistry. 37: 116093. PMID 33773393 DOI: 10.1016/j.bmc.2021.116093 |
0.356 |
|
| 2021 |
O'Connor C, Wallace-Povirk A, Ning C, Frühauf J, Tong N, Gangjee A, Matherly LH, Hou Z. Folate transporter dynamics and therapy with classic and tumor-targeted antifolates. Scientific Reports. 11: 6389. PMID 33737637 DOI: 10.1038/s41598-021-85818-x |
0.325 |
|
| 2020 |
Golani LK, Islam F, O'Connor C, Dekhne AS, Hou Z, Matherly LH, Gangjee A. Design, synthesis and biological evaluation of novel pyrrolo[2,3-d]pyrimidine as tumor-targeting agents with selectivity for tumor uptake by high affinity folate receptors over the reduced folate carrier. Bioorganic & Medicinal Chemistry. 28: 115544. PMID 32503687 DOI: 10.1016/J.Bmc.2020.115544 |
0.44 |
|
| 2020 |
Li Petri G, El Hassouni B, Sciarrillo R, Funel N, Mantini G, Zeeuw van der Laan EA, Cascioferro S, Avan A, Zucali PA, Zaffaroni N, Lagerweij T, Parrino B, Smid K, Deraco M, Granchi C, ... ... Matherly LH, et al. Impact of hypoxia on chemoresistance of mesothelioma mediated by the proton-coupled folate transporter, and preclinical activity of new anti-LDH-A compounds. British Journal of Cancer. PMID 32493992 DOI: 10.1038/S41416-020-0912-9 |
0.379 |
|
| 2020 |
Sarkisjan D, Julsing JR, El Hassouni B, Honeywell RJ, Kathmann I, Matherly LH, Lee YB, Kim DJ, Peters GJ. RX-3117 (Fluorocyclopentenyl-Cytosine)-Mediated Down-Regulation of DNA Methyltransferase 1 Leads to Protein Expression of Tumor-Suppressor Genes and Increased Functionality of the Proton-Coupled Folate Carrier. International Journal of Molecular Sciences. 21. PMID 32295203 DOI: 10.3390/Ijms21082717 |
0.417 |
|
| 2019 |
Dekhne AS, Ning C, Nayeen MJ, Shah K, Kalpage H, Fruhauf J, Wallace-Povirk A, O'Connor C, Hou Z, Kim S, Huttemann M, Gangjee A, Matherly LH. Cellular pharmacodynamics of a novel pyrrolo[3,2-d]pyrimidine inhibitor targeting mitochondrial and cytosolic one-carbon metabolism. Molecular Pharmacology. PMID 31707355 DOI: 10.1124/Mol.119.117937 |
0.392 |
|
| 2019 |
Xiang W, Dekhne A, Doshi A, O'Connor C, Hou Z, Matherly LH, Gangjee A. Discovery of amide-bridged pyrrolo[2,3-d]pyrimidines as tumor targeted classical antifolates with selective uptake by folate receptor α and inhibition of de novo purine nucleotide biosynthesis. Bioorganic & Medicinal Chemistry. 115125. PMID 31679978 DOI: 10.1016/J.Bmc.2019.115125 |
0.426 |
|
| 2019 |
Dekhne AS, Shah K, Ducker GS, Katinas JM, Wong-Roushar J, Nayeen MJ, Doshi A, Ning C, Bao X, Frühauf J, Liu J, Wallace-Povirk A, O'Connor C, Dzinic SH, White K, ... ... Matherly LH, et al. Novel pyrrolo[3,2-d]pyrimidine compounds target mitochondrial and cytosolic one-carbon metabolism with broad-spectrum antitumor efficacy. Molecular Cancer Therapeutics. PMID 31289137 DOI: 10.1158/1535-7163.Mct-19-0037 |
0.358 |
|
| 2019 |
Hou Z, O'Connor C, Frühauf J, Orr S, Kim S, Gangjee A, Matherly LH. Regulation of differential proton-coupled folate transporter gene expression in human tumors: Transactivation by KLF15 with NRF-1 and role of Sp1. The Biochemical Journal. PMID 30914440 DOI: 10.1042/Bcj20180394 |
0.427 |
|
| 2019 |
Frigerio B, Bizzoni C, Jansen G, Leamon CP, Peters GJ, Low PS, Matherly LH, Figini M. Folate receptors and transporters: biological role and diagnostic/therapeutic targets in cancer and other diseases. Journal of Experimental & Clinical Cancer Research : Cr. 38: 125. PMID 30867007 DOI: 10.1186/S13046-019-1123-1 |
0.333 |
|
| 2019 |
Nayeen J, Shah K, Dekhne A, Ning C, O'Connor C, Katinas JM, Wong J, Hou Z, Dann CE, Matherly LH, Gangjee A. Abstract 811: Multi-targeted inhibitors of mitochondrial one-carbon metabolism and cytosolicde novopurine synthesis enzymes as anti-tumor agents Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-811 |
0.3 |
|
| 2019 |
Tong N, Shah K, Gangjee A, O’Connor C, Porvirk AW, Dekhne A, Hou Z, Matherly LH. Abstract 789: Multi-targeted novel 5-substituted pyrrolo[3,2-d]pyrimidines with tumor-selective targeting and inhibition of cytosolic de novo purine biosynthesis and mitochondrial one-carbon metabolism Cancer Research. 79: 789-789. DOI: 10.1158/1538-7445.Sabcs18-789 |
0.447 |
|
| 2019 |
Wallace-Povirk A, O’Connor C, Dekhne A, Hou Z, Nayeen MJ, Shah K, Gangjee A, Matherly L. Abstract 4800: Targeting mitochondrial and cytosolic one-carbon metabolism in epithelial ovarian cancer via folate receptor alpha Cancer Research. 79: 4800-4800. DOI: 10.1158/1538-7445.Am2019-4800 |
0.46 |
|
| 2019 |
Ning C, Dekhne A, Nayeen MJ, Katinas JM, Wong J, Frühauf J, Bao X, O’Connor C, Wallace-Povirk A, Li J, Dann CE, Gangjee A, Matherly LH, Hou Z. Abstract 4794: Targeting mitochondrial and cytosolic one carbon metabolism of pancreatic adenocarcinoma via the proton-coupled folate transporter with novel 5-substituted pyrrolo[3,2-d]pyrimidine analogs Cancer Research. 79: 4794-4794. DOI: 10.1158/1538-7445.Am2019-4794 |
0.465 |
|
| 2019 |
Hou Z, O’Connor C, Ning C, Wallace-Povirk A, Frühauf J, Nayeen MJ, Gangjee A, Matherly LH. Abstract 4791: Impact of folate transport redundancies on the therapy with tumor-targeted and untargeted antifolates Cancer Research. 79: 4791-4791. DOI: 10.1158/1538-7445.Am2019-4791 |
0.461 |
|
| 2018 |
Patki M, McFall T, Rosati R, Huang Y, Malysa A, Polin L, Fielder A, Wilson MR, Lonardo F, Back J, Li J, Matherly LH, Bepler G, Ratnam M. Chronic p27 Induction by Dexamethasone Causes Senescence Phenotype and Permanent Cell Cycle Blockade in Lung Adenocarcinoma Cells Over-expressing Glucocorticoid Receptor. Scientific Reports. 8: 16006. PMID 30375484 DOI: 10.1038/S41598-018-34475-8 |
0.372 |
|
| 2018 |
Ravindra M, Wilson MR, Tong N, O'Connor C, Karim M, Polin L, Wallace-Povirk A, White K, Kushner J, Hou Z, Matherly LH, Gangjee A. Fluorine-Substituted Pyrrolo[2,3- d]Pyrimidine Analogues with Tumor Targeting via Cellular Uptake by Folate Receptor α and the Proton-Coupled Folate Transporter and Inhibition of de Novo Purine Nucleotide Biosynthesis. Journal of Medicinal Chemistry. PMID 29701475 DOI: 10.1021/Acs.Jmedchem.8B00408 |
0.461 |
|
| 2018 |
Shah K, Raghavan S, Hou Z, Matherly LH, Gangjee A. Development and validation of chemical features-based proton-coupled folate transporter/activity and reduced folate carrier/activity models (pharmacophores). Journal of Molecular Graphics & Modelling. 81: 125-133. PMID 29550744 DOI: 10.1016/J.Jmgm.2018.02.007 |
0.433 |
|
| 2018 |
Ravindra M, Wallace-Povirk A, Karim MA, Wilson MR, O'Connor CE, White K, Kushner J, Polin LA, George C, Hou Z, Matherly LH, Gangjee A. Tumor Targeting with Novel Pyridyl 6-Substituted Pyrrolo[2,3-d]Pyrimidine Antifolates Via Cellular Uptake by Folate Receptor α and the Proton-coupled Folate Transporter and Inhibition of De Novo Purine Nucleotide Biosynthesis. Journal of Medicinal Chemistry. PMID 29425443 DOI: 10.1021/Acs.Jmedchem.7B01708 |
0.459 |
|
| 2018 |
Dekhne AS, Ducker GS, Frühauf J, Shah K, Nayeen MJ, Wallace-Povirk A, O'Connor C, Hou Z, Polin L, Gangjee A, Rabinowitz JD, Matherly LH. Abstract 3980: Dual targeting mitochondrial and cytosolic one-carbon metabolism via the proton-coupled folate transporter with novel 5-substituted pyrrolo[3,2-d]pyrimidine antifolates Cancer Research. 78: 3980-3980. DOI: 10.1158/1538-7445.Am2018-3980 |
0.439 |
|
| 2018 |
Nayeen J, Shah K, Gangjee A, Dekhne A, Hou Z, Matherly LH. Abstract 1656: First-in-class, fluorinated folate receptor specific agents that target tumor cells via inhibition of serine hydroxymethyltransferase 2 (SHMT2) and 5-aminoimidazole-4-carboxamide formyltransferase (AICARFTase) Cancer Research. 78: 1656-1656. DOI: 10.1158/1538-7445.Am2018-1656 |
0.433 |
|
| 2017 |
Matherly LH, Hou Z, Gangjee A. The promise and challenges of exploiting the proton-coupled folate transporter for selective therapeutic targeting of cancer. Cancer Chemotherapy and Pharmacology. PMID 29127457 DOI: 10.1007/S00280-017-3473-8 |
0.443 |
|
| 2017 |
Giovannetti E, Zucali PA, Assaraf YG, Funel N, Gemelli M, Stark M, Thunnissen E, Hou Z, Muller IB, Struijs EA, Perrino M, Jansen G, Matherly LH, Peters GJ. Role of proton-coupled folate transporter in pemetrexed-resistance of mesothelioma: clinical evidence and new pharmacological tools. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 28945836 DOI: 10.1093/Annonc/Mdx499 |
0.341 |
|
| 2017 |
Deis SM, Doshi A, Hou Z, Matherly LH, Gangjee A, Dann CE. Correction to Structural and Enzymatic Analysis of Tumor-Targeted Antifolates That Inhibit Glycinamide Ribonucleotide Formyltransferase. Biochemistry. PMID 28186409 DOI: 10.1021/Acs.Biochem.7B00092 |
0.319 |
|
| 2017 |
Hou Z, Gattoc L, O'Connor C, Yang S, Wallace-Povirk A, George C, Orr S, Polin L, White K, Kushner J, Morris RT, Gangjee A, Matherly LH. Dual targeting of epithelial ovarian cancer via folate receptor α and the proton-coupled folate transporter with 6-substituted pyrrolo[2,3-d]pyrimidine antifolates. Molecular Cancer Therapeutics. PMID 28138029 DOI: 10.1158/1535-7163.Mct-16-0444 |
0.489 |
|
| 2017 |
Hou Z, O'Connor C, Orr S, Matherly LH. Abstract 5491: Identification of transcriptional controls responsible for differential gene expression of the proton-coupled folate transporter in human solid tumors Cancer Research. 77: 5491-5491. DOI: 10.1158/1538-7445.Am2017-5491 |
0.394 |
|
| 2017 |
Tong N, Gangjee A, Povrik AW, O’Connor C, Dekhneb AA, Hou Z, Matherly LH. Abstract 5123: Targeted thieno[2,3-d]pyrimidines with fluorinated phenyl side chains as antitumor agents Cancer Research. 77: 5123-5123. DOI: 10.1158/1538-7445.Am2017-5123 |
0.471 |
|
| 2017 |
Gangjee A, Mohan R, Ravindra M, Wallace-Povirk A, O’Connor C, Dekhne A, Hou Z, Matherly LH. Abstract 3239: Selective tumor targeting with 5-substituted pyrrolo[2,3-d]pyrimidines with heteroatom bridge substitution Cancer Research. 77: 3239-3239. DOI: 10.1158/1538-7445.Am2017-3239 |
0.477 |
|
| 2016 |
Edwards H, Rubenstein M, Dombkowski AA, Caldwell JT, Chu R, Xavier AC, Thummel R, Neely M, Matherly LH, Ge Y, Taub JW. Gene Signature of High White Blood Cell Count in B-Precursor Acute Lymphoblastic Leukemia. Plos One. 11: e0161539. PMID 27536776 DOI: 10.1371/Journal.Pone.0161539 |
0.336 |
|
| 2016 |
Wilson MR, Hou Z, Wilson LJ, Ye J, Matherly LH. Functional and mechanistic roles of the human proton-coupled folate transporter transmembrane domain 6-7 linker. The Biochemical Journal. PMID 27514717 DOI: 10.1042/Bcj20160399 |
0.447 |
|
| 2016 |
Golani LK, Wallace-Povirk A, Deis SM, Wong JE, Ke J, Gu X, Raghavan S, Wilson MR, Li X, Polin LA, de Waal PW, White K, Kushner J, O'Connor CE, Hou Z, ... ... Matherly LH, et al. Tumor Targeting with Novel 6-Substituted Pyrrolo [2,3-d] Pyrimidine Antifolates with Heteroatom Bridge Substitutions Via Cellular Uptake by Folate Receptor α and the Proton-coupled Folate Transporter and Inhibition of De Novo Purine Nucleotide Biosynthesis. Journal of Medicinal Chemistry. PMID 27458733 DOI: 10.1021/Acs.Jmedchem.6B00594 |
0.43 |
|
| 2016 |
Deis SM, Doshi A, Hou Z, Matherly LH, Gangjee A, Dann Iii CE. Structural and enzymatic analysis of tumor-targeted antifolates that inhibit glycinamide ribonucleotide formyltransferase. Biochemistry. PMID 27439469 DOI: 10.1021/Acs.Biochem.6B00412 |
0.472 |
|
| 2016 |
Golani LK, George C, Zhao S, Raghavan S, Orr S, Wallace A, Wilson MR, Hou Z, Matherly LH, Gangjee A. Correction to Structure-Activity Profiles of Novel 6-Substituted Pyrrolo[2,3-d]pyrimidine Thienoyl Antifolates with Modified Amino Acids for Cellular Uptake by Folate Receptors α and β and the Proton-Coupled Folate Transporter. Journal of Medicinal Chemistry. PMID 27082426 DOI: 10.1021/Acs.Jmedchem.6B00502 |
0.356 |
|
| 2016 |
Wilson MR, Hou Z, Yang S, Polin L, Kushner J, White K, Huang J, Ratnam M, Gangjee A, Matherly LH. Targeting Non-Squamous Non-Small Cell Lung Cancer Via the Proton-Coupled Folate Transporter with 6-Substituted Pyrrolo[2,3-d]Pyrimidine Thienoyl Antifolates. Molecular Pharmacology. PMID 26837243 DOI: 10.1124/Mol.115.102798 |
0.397 |
|
| 2016 |
Gangjee A, Tong N, Povrik AW, Hou Z, Matherly LH. Abstract 4836: Targeted antifolates with thienoyl regioisomers in the side chain result in improved selectivity and potency against KB human tumor cells Cancer Research. 76: 4836-4836. DOI: 10.1158/1538-7445.Am2016-4836 |
0.492 |
|
| 2016 |
Wilson MR, Ravindraa MP, Wallace-Povirk A, Polin L, Hou Z, Gangjee A, Matherly LH. Abstract 4791: Targeting ovarian cancer with novel 6-substituted pyrrolo [2,3-d] pyrimidine fluorinated antifolates via cellular uptake by folate receptor á and the proton-coupled folate transporter Cancer Research. 76: 4791-4791. DOI: 10.1158/1538-7445.Am2016-4791 |
0.376 |
|
| 2016 |
Gangjee A, Xiang W, Dehkne A, Wilson MR, Wallace-Povrik A, O’Connor C, Hou Z, Matherly LH. Abstract 1365: Pseudo-cis and pseudo-trans amide conformations lead to potent targeted antifolates that are selectively transported by FR over RFC Cancer Research. 76: 1365-1365. DOI: 10.1158/1538-7445.Am2016-1365 |
0.428 |
|
| 2016 |
Raghavan S, Gangjee A, Matherly LH. Abstract 1362: Novel proton coupled folate transporter (PCFT) and reduced folate carrier (RFC) pharmacophore models for development of transporter-selective antifolates Cancer Research. 76: 1362-1362. DOI: 10.1158/1538-7445.Am2016-1362 |
0.434 |
|
| 2016 |
Gangjee A, Ravindra MP, Wilson MR, Povrik AW, Hou LP, O’Connor C, Hou Z, Matherly LH. Abstract 1359: Design, synthesis and evaluation of fluorinated antifolates for improved selectivity and potency against tumor cells Cancer Research. 76: 1359-1359. DOI: 10.1158/1538-7445.Am2016-1359 |
0.454 |
|
| 2016 |
Patki M, Huang Y, Wilson M, Fielder A, Matherly L, Polin L, Ratnam M. Long-term treatment with dexamethasone induces senescence and progressive loss of proliferation potential in lung adenocarcinoma cells expressing high levels of the glucocorticoid receptor Journal of Thoracic Oncology. 11: S36. DOI: 10.1016/J.Jtho.2015.12.061 |
0.385 |
|
| 2015 |
Wang L, Wallace A, Raghavan S, Deis SM, Wilson MR, Yang S, Polin L, White K, Kushner J, Orr S, George C, O'Connor C, Hou Z, Mitchell-Ryan S, Dann CE, ... Matherly LH, et al. 6-Substituted Pyrrolo[2,3-d]pyrimidine Thienoyl Regioisomers as Targeted Antifolates for Folate Receptor α and the Proton-Coupled Folate Transporter in Human Tumors. Journal of Medicinal Chemistry. PMID 26317331 DOI: 10.1021/Acs.Jmedchem.5B00801 |
0.445 |
|
| 2015 |
Wilson MR, Kugel S, Huang J, Wilson LJ, Wloszczynski PA, Ye J, Matherly LH, Hou Z. Structural determinants of human proton-coupled folate transporter oligomerization: role of GXXXG motifs and identification of oligomeric interfaces at transmembrane domains 3 and 6. The Biochemical Journal. PMID 25877470 DOI: 10.1042/Bj20150169 |
0.423 |
|
| 2015 |
Wang Y, Mitchell-Ryan S, Raghavan S, George C, Orr S, Hou Z, Matherly LH, Gangjee A. Novel 5-substituted pyrrolo[2,3-d]pyrimidines as dual inhibitors of glycinamide ribonucleotide formyltransferase and 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase and as potential antitumor agents. Journal of Medicinal Chemistry. 58: 1479-93. PMID 25602637 DOI: 10.1021/Jm501787C |
0.44 |
|
| 2015 |
Wilson MR, Hou Z, Wang L, Wang S, Ratnam M, Gangjee A, Matherly L. Abstract 5403: Targeted therapy of non-small cell lung cancer (NSCLC) by novel 6-pyrrolo[2,3-d]pyrimidine thienoyl antifolates with selective transport by the proton-coupled folate transporter (PCFT) Cancer Research. 75: 5403-5403. DOI: 10.1158/1538-7445.Am2015-5403 |
0.445 |
|
| 2015 |
Leamon CP, Reddy JA, Vlahov IR, You F, Klein HF, Kleindl PJ, Nelson M, Vetzel M, Klein PJ, Matherly LH, Gangjee A. Abstract 4488: Folate receptor targeted therapy using small molecule drug conjugates constructed with high affinity antifolate ligands Cancer Research. 75: 4488-4488. DOI: 10.1158/1538-7445.Am2015-4488 |
0.367 |
|
| 2015 |
Hou Z, Orr S, George C, Wallace A, Matherly LH, Wang L, Yang S, Gandjee A. Abstract 4483: Impact of loss of folate receptor alpha on antitumor effects of novel 6-substituted pyrrolo[2,3-d]pyrimidine antifolates with substrate activities for both folate receptors and the proton-coupled folate transporter Cancer Research. 75: 4483-4483. DOI: 10.1158/1538-7445.Am2015-4483 |
0.471 |
|
| 2015 |
Wallace-Povirk A, Tong N, O'Connor C, Hou Z, Gangjee A, Matherly L, Zhou X. Abstract 3983: Tumor-targeting with novel dual-targeted 6-substituted thieno[2,3-d]pyrimidine antifolates via cellular uptake by folate receptor α, and inhibition of de novo purine nucleotide biosynthesis Cancer Research. 75: 3983-3983. DOI: 10.1158/1538-7445.Am2015-4481 |
0.482 |
|
| 2015 |
Vlahov IR, You F, Klein HF, Kleindl PJ, Nelson M, Vetzel M, Reddy JA, Leamon CP, Matherly LH, Gangjee A. Abstract 4393: Design and synthesis of novel conjugates for targeting the folate receptor: Exploiting cytotoxic GARFTase inhibitors for delivering additional chemotherapeutic payloads to cancer cells Cancer Research. 75: 4393-4393. DOI: 10.1158/1538-7445.Am2015-4393 |
0.339 |
|
| 2015 |
Giovannetti E, Zucali PA, Assaraf YG, Funel N, Gemelli M, Stark M, Leon LG, Hou Z, Perrino M, Matherly LH, Peters GJ. Abstract 4335: Role of proton-coupled folate transporter expression in resistance of mesothelioma patients treated with pemetrexed Cancer Research. 75: 4335-4335. DOI: 10.1158/1538-7445.Am2015-4335 |
0.344 |
|
| 2014 |
Golani LK, George C, Zhao S, Raghavan S, Orr S, Wallace A, Wilson MR, Hou Z, Matherly LH, Gangjee A. Structure-activity profiles of novel 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolates with modified amino acids for cellular uptake by folate receptors α and β and the proton-coupled folate transporter. Journal of Medicinal Chemistry. 57: 8152-66. PMID 25234128 DOI: 10.1021/Jm501113M |
0.433 |
|
| 2014 |
Wilson MR, Hou Z, Matherly LH. Substituted cysteine accessibility reveals a novel transmembrane 2-3 reentrant loop and functional role for transmembrane domain 2 in the human proton-coupled folate transporter. The Journal of Biological Chemistry. 289: 25287-95. PMID 25053408 DOI: 10.1074/Jbc.M114.578252 |
0.392 |
|
| 2014 |
Hou Z, Orr S, Matherly LH. Post-transcriptional regulation of the human reduced folate carrier as a novel adaptive mechanism in response to folate excess or deficiency. Bioscience Reports. 34. PMID 24949876 DOI: 10.1042/Bsr20140065 |
0.387 |
|
| 2014 |
Hou Z, Matherly LH. Biology of the major facilitative folate transporters SLC19A1 and SLC46A1. Current Topics in Membranes. 73: 175-204. PMID 24745983 DOI: 10.1016/B978-0-12-800223-0.00004-9 |
0.423 |
|
| 2014 |
Patki M, Gadgeel S, Huang Y, McFall T, Shields AF, Matherly LH, Bepler G, Ratnam M. Glucocorticoid receptor status is a principal determinant of variability in the sensitivity of non-small-cell lung cancer cells to pemetrexed Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 9: 519-526. PMID 24736075 DOI: 10.1097/Jto.0000000000000111 |
0.307 |
|
| 2014 |
Matherly LH, Wilson MR, Hou Z. The major facilitative folate transporters solute carrier 19A1 and solute carrier 46A1: biology and role in antifolate chemotherapy of cancer. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 42: 632-49. PMID 24396145 DOI: 10.1124/Dmd.113.055723 |
0.416 |
|
| 2014 |
Hales EC, Taub JW, Matherly LH. New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia. Cellular Signalling. 26: 149-61. PMID 24140475 DOI: 10.1016/J.Cellsig.2013.09.021 |
0.342 |
|
| 2014 |
Hou Z, Wilson MR, Wilson L, Desmoulin SK, Huang J, Matherly LH. Abstract 783: Identification of structural determinants of human proton-coupled folate transporter oligomerization Cancer Research. 74: 783-783. DOI: 10.1158/1538-7445.Am2014-783 |
0.806 |
|
| 2014 |
Wilson MR, Hou Z, Matherly LH. Abstract 782: Transmembrane 2-3 loop domain of the proton coupled folate transporter (PCFT) forms a novel “reentrant loop” structure and is functionally important Cancer Research. 74: 782-782. DOI: 10.1158/1538-7445.Am2014-782 |
0.442 |
|
| 2014 |
Parker N, Cherian C, Matherly L, Leamon CP. Abstract 4591: The folate receptor-targeted agents, vintafolide and etarfolatide, are not substrates for the reduced folate carrier or the proton-coupled folate transporter Cancer Research. 74: 4591-4591. DOI: 10.1158/1538-7445.Am2014-4591 |
0.454 |
|
| 2014 |
Cherian C, Wang L, Wallace A, Orr S, Hou Z, Gangjee A, Matherly LH. Abstract 2706: Tumor-targeting with novel pyridyl 6-substituted pyrrolo[2,3-d]pyrimidine antifolates via cellular uptake by folate receptor (FR) α and the proton-coupled folate transporter (PCFT) and inhibition ofde novopurine nucleotide biosynthesis Cancer Research. 74: 2706-2706. DOI: 10.1158/1538-7445.Am2014-2706 |
0.449 |
|
| 2014 |
Golani LK, Gangjee A, Cherian C, Orr S, Mitchell-Ryan S, Polin L, Wallace A, Matherly LH. Abstract 1620: Synthesis and preclinical evaluation of novel 6-substituted pyrrolo[2,3-d]pyrimidines as targeted antifolates Cancer Research. 74: 1620-1620. DOI: 10.1158/1538-7445.Am2014-1620 |
0.484 |
|
| 2013 |
Mitchell-Ryan S, Wang Y, Raghavan S, Ravindra MP, Hales E, Orr S, Cherian C, Hou Z, Matherly LH, Gangjee A. Discovery of 5-substituted pyrrolo[2,3-d]pyrimidine antifolates as dual-acting inhibitors of glycinamide ribonucleotide formyltransferase and 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase in de novo purine nucleotide biosynthesis: implications of inhibiting 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase to ampk activation and antitumor activity. Journal of Medicinal Chemistry. 56: 10016-32. PMID 24256410 DOI: 10.1021/Jm401328U |
0.413 |
|
| 2013 |
Wang Y, Cherian C, Orr S, Mitchell-Ryan S, Hou Z, Raghavan S, Matherly LH, Gangjee A. Tumor-targeting with novel non-benzoyl 6-substituted straight chain pyrrolo[2,3-d]pyrimidine antifolates via cellular uptake by folate receptor α and inhibition of de novo purine nucleotide biosynthesis. Journal of Medicinal Chemistry. 56: 8684-95. PMID 24111942 DOI: 10.1021/Jm401139Z |
0.378 |
|
| 2013 |
Caldwell JT, Edwards H, Dombkowski AA, Buck SA, Matherly LH, Ge Y, Taub JW. Overexpression of GATA1 confers resistance to chemotherapy in acute megakaryocytic Leukemia. Plos One. 8: e68601. PMID 23874683 DOI: 10.1371/Journal.Pone.0068601 |
0.389 |
|
| 2013 |
Hales EC, Orr SM, Larson Gedman A, Taub JW, Matherly LH. Notch1 receptor regulates AKT protein activation loop (Thr308) dephosphorylation through modulation of the PP2A phosphatase in phosphatase and tensin homolog (PTEN)-null T-cell acute lymphoblastic leukemia cells. The Journal of Biological Chemistry. 288: 22836-48. PMID 23788636 DOI: 10.1074/Jbc.M113.451625 |
0.771 |
|
| 2013 |
Cherian C, Kugel Desmoulin S, Wang L, Polin L, White K, Kushner J, Stout M, Hou Z, Gangjee A, Matherly LH. Therapeutic targeting malignant mesothelioma with a novel 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate via its selective uptake by the proton-coupled folate transporter. Cancer Chemotherapy and Pharmacology. 71: 999-1011. PMID 23412628 DOI: 10.1007/S00280-013-2094-0 |
0.397 |
|
| 2013 |
Hou Z, Orr S, Etnyre E, Cherian C, Matherly L. Abstract 873: Acute regulation of human reduced folate carrier by folates as a novel adaptive mechanism to folate deprivation. Cancer Research. 73: 873-873. DOI: 10.1158/1538-7445.Am2013-873 |
0.464 |
|
| 2013 |
Mitchell-Ryan SK, Wang L, Orr S, Kugel S, Cherian C, Gangjee A, Matherly LH. Abstract 5494: Novel 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate regioisomers target folate receptor alpha positive ovarian cancer cells via inhibition of de novo purine nucleotide biosynthesis. Cancer Research. 73: 5494-5494. DOI: 10.1158/1538-7445.Am2013-5494 |
0.459 |
|
| 2013 |
Cherian C, Wang Y, Mitchell-Ryan S, Orr S, Hou Z, Gangjee A, Matherly LH. Abstract 5493: Tumor-targeting with novel non-benzoyl 6-substituted pyrrolo[2,3-d]pyrimidine antifolates via cellular uptake by folate receptor α and inhibition ofde novopurine nucleotide biosynthesis. Cancer Research. 73: 5493-5493. DOI: 10.1158/1538-7445.Am2013-5493 |
0.43 |
|
| 2013 |
Gangjee A, Zhao S, Kumar L, Cherian C, Orr S, Huang J, Hou Z, Matherly LH. Abstract 5492: Study the variation of the glutamate moiety of AG94, a targeted, potent GARFTase inhibitor, as antitumor agents with the 2-amino-6-substituted pyrrolo[2,3-d]pyrimidine scaffold. Cancer Research. 73: 5492-5492. DOI: 10.1158/1538-7445.Am2013-5492 |
0.4 |
|
| 2013 |
Hales EC, Orr SM, Gedman AL, Taub JW, Matherly LH. Abstract 4116: Notch1 regulates AKT-T308 dephosphorylation through modulation of the PP2A phosphatase in GSI-resistant T-cell acute lymphoblastic leukemia (T-ALL) cells. Cancer Research. 73: 4116-4116. DOI: 10.1158/1538-7445.Am2013-4116 |
0.392 |
|
| 2012 |
Desmoulin SK, Hou Z, Gangjee A, Matherly LH. The human proton-coupled folate transporter: Biology and therapeutic applications to cancer. Cancer Biology & Therapy. 13: 1355-73. PMID 22954694 DOI: 10.4161/Cbt.22020 |
0.808 |
|
| 2012 |
Desmoulin SK, Wang L, Polin L, White K, Kushner J, Stout M, Hou Z, Cherian C, Gangjee A, Matherly LH. Functional loss of the reduced folate carrier enhances the antitumor activities of novel antifolates with selective uptake by the proton-coupled folate transporter. Molecular Pharmacology. 82: 591-600. PMID 22740639 DOI: 10.1124/Mol.112.079004 |
0.807 |
|
| 2012 |
Menter A, Thrash B, Cherian C, Matherly LH, Wang L, Gangjee A, Morgan JR, Maeda DY, Schuler AD, Kahn SJ, Zebala JA. Intestinal transport of aminopterin enantiomers in dogs and humans with psoriasis is stereoselective: evidence for a mechanism involving the proton-coupled folate transporter. The Journal of Pharmacology and Experimental Therapeutics. 342: 696-708. PMID 22653877 DOI: 10.1124/Jpet.112.195479 |
0.302 |
|
| 2012 |
Xie C, Edwards H, Lograsso SB, Buck SA, Matherly LH, Taub JW, Ge Y. Valproic acid synergistically enhances the cytotoxicity of clofarabine in pediatric acute myeloid leukemia cells. Pediatric Blood & Cancer. 59: 1245-51. PMID 22488775 DOI: 10.1002/Pbc.24152 |
0.303 |
|
| 2012 |
Wang L, Cherian C, Kugel Desmoulin S, Mitchell-Ryan S, Hou Z, Matherly LH, Gangjee A. Synthesis and biological activity of 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl regioisomers as inhibitors of de novo purine biosynthesis with selectivity for cellular uptake by high affinity folate receptors and the proton-coupled folate transporter over the reduced folate carrier. Journal of Medicinal Chemistry. 55: 1758-70. PMID 22243528 DOI: 10.1021/Jm201688N |
0.438 |
|
| 2012 |
Hou Z, Desmoulin SK, Etnyre E, Olive M, Hsiung B, Cherian C, Wloszczynski PA, Moin K, Matherly LH. Identification and functional impact of homo-oligomers of the human proton-coupled folate transporter Journal of Biological Chemistry. 287: 4982-4995. PMID 22179615 DOI: 10.1074/Jbc.M111.306860 |
0.812 |
|
| 2012 |
Gangjee A, Kumar L, Cherian C, Orr S, Etnyre E, Matherly LH. Abstract 4765: Synthesis and evaluation of nonclassical 6-substituted pyrrolo[2,3-d]pyrimidine antifolates: Role of terminal amino acid moiety in membrane transport and antitumor activity. Cancer Research. 72: 4765-4765. DOI: 10.1158/1538-7445.Am2012-4765 |
0.485 |
|
| 2012 |
Cherian C, Desmoulin SK, Wang L, Polin L, White K, Kushner J, Stout M, Hou Z, Gangjee A, Matherly LH. Abstract 3826: Therapeutic targeting malignant mesothelioma with a novel 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate via its selective uptake by the proton-coupled folate transporter Cancer Research. 72: 3826-3826. DOI: 10.1158/1538-7445.Am2012-3826 |
0.816 |
|
| 2012 |
Desmoulin SK, Wang L, Polin L, White K, Kushner J, Stout M, Hou Z, Cherian C, Gangjee A, Matherly LH. Abstract 3825: The impact of the reduced folate carrier on the collateral sensitivity of novel 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolates with selective uptake by the proton-coupled folate transporter Cancer Research. 72: 3825-3825. DOI: 10.1158/1538-7445.Am2012-3825 |
0.799 |
|
| 2012 |
Wang Y, Ravindra MP, Ryan SM, Kisliuk RL, Matherly LH, Gangjee A. Abstract 3824: Design, synthesis and biological evaluation of 4-atom side chain pemetrexed (PMX) homolog AG127 as a potent inhibitor of tumors expressing folate receptors via 5-aminoimidazole-4-carboxamide ribonucleotide formyl transferase (AICARFTase) inhibition Cancer Research. 72: 3824-3824. DOI: 10.1158/1538-7445.Am2012-3824 |
0.458 |
|
| 2012 |
Gangjee A, Zhao S, Wang L, Orr S, Etnyre E, Raghavan S, Matherly LH, Kisliuk RL. Abstract 3823: 2-Methyl-6-substituted pyrrolo[2,3-d]pyrimidine classical antifolates as selective folate receptor substrates, glycinamide ribonucleotide formyltransferase inhibitors and antitumor agents Cancer Research. 72: 3823-3823. DOI: 10.1158/1538-7445.Am2012-3823 |
0.507 |
|
| 2012 |
Mitchell-Ryan SK, Wang Y, Cherian C, Etnyre E, Hou Z, Gangjee A, Matherly LH. Abstract 3822: A tumor-targeted 5-pyrrolo[2,3-d]pyrimidine antifolate is a selective substrate for folate receptor ≤ and potent inhibitor of 5-amino-4-carboxamide formyltransferase inde novopurine nucleotide biosynthesis Cancer Research. 72: 3822-3822. DOI: 10.1158/1538-7445.Am2012-3822 |
0.452 |
|
| 2012 |
Hales EC, Orr S, Gedman AL, Taub J, Matherly L. Abstract 2226: Mechanisms for cross-talk between Notch1 and AKT signaling in T-cell acute lymphoblastic leukemia Cancer Research. 72: 2226-2226. DOI: 10.1158/1538-7445.Am2012-2226 |
0.421 |
|
| 2011 |
Kugel Desmoulin S, Wang L, Hales E, Polin L, White K, Kushner J, Stout M, Hou Z, Cherian C, Gangjee A, Matherly LH. Therapeutic targeting of a novel 6-substituted pyrrolo [2,3-d]pyrimidine thienoyl antifolate to human solid tumors based on selective uptake by the proton-coupled folate transporter. Molecular Pharmacology. 80: 1096-107. PMID 21940787 DOI: 10.1124/Mol.111.073833 |
0.466 |
|
| 2011 |
Wang L, Desmoulin SK, Cherian C, Polin L, White K, Kushner J, Fulterer A, Chang MH, Mitchell-Ryan S, Stout M, Romero MF, Hou Z, Matherly LH, Gangjee A. Synthesis, biological, and antitumor activity of a highly potent 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitor with proton-coupled folate transporter and folate receptor selectivity over the reduced folate carrier that inhibits β-glycinamide ribonucleotide formyltransferase. Journal of Medicinal Chemistry. 54: 7150-64. PMID 21879757 DOI: 10.1021/Jm200739E |
0.797 |
|
| 2011 |
Xie C, Edwards H, Xu X, LoGrasso SB, Stout ML, Buck S, Matherly LH, Taub J, Ge Y. Abstract 4351: p53 is a critical determinant of the antileukemic interactions between histone deacetylase inhibitors and chemotherapy drugs in pediatric acute myeloid leukemia cells Cancer Research. 71: 4351-4351. DOI: 10.1158/1538-7445.Am2011-4351 |
0.381 |
|
| 2011 |
Wang Y, Mitchell S, Cherian C, Desmoulin SK, Hou Z, Kisliuk RL, Matherly LH, Gangjee A. Abstract 3250: Design, synthesis and biological evaluation of side chain pemetrexed (PMX) analogues as potent inhibitors of tumors expressing folate receptors via GARFTase inhibition Cancer Research. 71: 3250-3250. DOI: 10.1158/1538-7445.Am2011-3250 |
0.81 |
|
| 2011 |
Hales EC, Gedman AL, Ge Y, Taub JW, Matherly LH. Abstract 2881: Posttranslational inactivation of PTEN promoted by loss of Notch1 signaling in T-ALL Cancer Research. 71: 2881-2881. DOI: 10.1158/1538-7445.Am2011-2881 |
0.379 |
|
| 2011 |
Desmoulin SK, Wang L, Tait L, Polin L, Hou Z, Cherian C, Gangjee A, Matherly LH. Abstract 2528: Therapeutic targeting of a novel 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate to human solid tumors based on selective uptake by PCFT Cancer Research. 71: 2528-2528. DOI: 10.1158/1538-7445.Am2011-2528 |
0.813 |
|
| 2011 |
Wang L, Cherian C, Desmoulin SK, Hou Z, Matherly LH, Gangjee A. Abstract 1364: Design, synthesis and evaluation of potent antiproliferative and cytotoxic antifolates with selective FRs and PCFT transport over RFC and potent GARFTase inhibition Cancer Research. 71: 1364-1364. DOI: 10.1158/1538-7445.Am2011-1364 |
0.797 |
|
| 2010 |
Desmoulin SK, Wang Y, Wu J, Stout M, Hou Z, Fulterer A, Chang MH, Romero MF, Cherian C, Gangjee A, Matherly LH. Targeting the proton-coupled folate transporter for selective delivery of 6-substituted pyrrolo[2,3-d]pyrimidine antifolate inhibitors of de novo purine biosynthesis in the chemotherapy of solid tumors. Molecular Pharmacology. 78: 577-87. PMID 20601456 DOI: 10.1124/Mol.110.065896 |
0.812 |
|
| 2010 |
Hou Z, Wu J, Ye J, Cherian C, Matherly LH. Substrate-specific binding and conformational changes involving Ser313 and transmembrane domain 8 of the human reduced folate carrier, as determined by site-directed mutagenesis and protein cross-linking. The Biochemical Journal. 430: 265-74. PMID 20557288 DOI: 10.1042/Bj20100181 |
0.392 |
|
| 2010 |
Wang L, Cherian C, Desmoulin SK, Polin L, Deng Y, Wu J, Hou Z, White K, Kushner J, Matherly LH, Gangjee A. Synthesis and antitumor activity of a novel series of 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors and the proton-coupled folate transporter over the reduced folate carrier for cellular entry. Journal of Medicinal Chemistry. 53: 1306-18. PMID 20085328 DOI: 10.1021/Jm9015729 |
0.807 |
|
| 2010 |
Hou Z, Cherian C, Drews J, Wu J, Matherly LH. Identification of the minimal functional unit of the homo-oligomeric human reduced folate carrier. The Journal of Biological Chemistry. 285: 4732-40. PMID 20018840 DOI: 10.1074/Jbc.M109.086033 |
0.436 |
|
| 2010 |
Medyouf H, Gao X, Armstrong F, Gusscott S, Liu Q, Gedman AL, Matherly LH, Schultz KR, Pflumio F, You MJ, Weng AP. Acute T-cell leukemias remain dependent on Notch signaling despite PTEN and INK4A/ARF loss. Blood. 115: 1175-84. PMID 20008304 DOI: 10.1182/Blood-2009-04-214718 |
0.382 |
|
| 2010 |
Xu X, Xie C, Edwards H, Zhou H, Buck S, Matherly L, Taub J, Ge Y. Inhibition of Histone Deacetylases 1 and 6 Enhances Ara-C-Induced Apoptosis In Pediatric Acute Myeloid Leukemia Cells Blood. 116: 3275-3275. DOI: 10.1182/Blood.V116.21.3275.3275 |
0.363 |
|
| 2010 |
Kugel-Desmoulin S, Wang L, Tait L, Hou Z, Cherian C, Gangjee A, Matherly LH. Abstract 4546: Expression profiling of the major folate facilitative transporters in human tumors and normal tissues Cancer Research. 70: 4546-4546. DOI: 10.1158/1538-7445.Am10-4546 |
0.453 |
|
| 2010 |
Gangjee A, Wang L, Cherian C, Desmoulin SK, Hou Z, Kisliuk RL, Matherly LH. Abstract 4542: The design, synthesis andin vitroevaluation of selective FR α and β and PCFT substrates with potent GARFTase inhibitory activity as antitumor agents Cancer Research. 70: 4542-4542. DOI: 10.1158/1538-7445.Am10-4542 |
0.798 |
|
| 2010 |
Gedman ALL, Dombkowski A, Ge Y, Taub JW, Matherly LH. Abstract 4360: Loss of NOTCH1 is associated with decreased expression of hsa-miR-125a-5p in T-cell acute lymphoblastic leukemia: Implications for using NOTCH1 inhibition in chemotherapy Cancer Research. 70: 4360-4360. DOI: 10.1158/1538-7445.Am10-4360 |
0.379 |
|
| 2009 |
Edwards H, Xie C, LaFiura KM, Dombkowski AA, Buck SA, Boerner JL, Taub JW, Matherly LH, Ge Y. RUNX1 regulates phosphoinositide 3-kinase/AKT pathway: role in chemotherapy sensitivity in acute megakaryocytic leukemia. Blood. 114: 2744-52. PMID 19638627 DOI: 10.1182/Blood-2008-09-179812 |
0.339 |
|
| 2009 |
Deng Y, Zhou X, Kugel Desmoulin S, Wu J, Cherian C, Hou Z, Matherly LH, Gangjee A. Synthesis and biological activity of a novel series of 6-substituted thieno[2,3-d]pyrimidine antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors over the reduced folate carrier and proton-coupled folate transporter for cellular entry. Journal of Medicinal Chemistry. 52: 2940-51. PMID 19371039 DOI: 10.1021/Jm8011323 |
0.45 |
|
| 2009 |
Larson Gedman A, Chen Q, Kugel Desmoulin S, Ge Y, LaFiura K, Haska CL, Cherian C, Devidas M, Linda SB, Taub JW, Matherly LH. The impact of NOTCH1, FBW7 and PTEN mutations on prognosis and downstream signaling in pediatric T-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group. Leukemia. 23: 1417-25. PMID 19340001 DOI: 10.1038/Leu.2009.64 |
0.759 |
|
| 2009 |
Zhao R, Matherly LH, Goldman ID. Membrane transporters and folate homeostasis: intestinal absorption and transport into systemic compartments and tissues. Expert Reviews in Molecular Medicine. 11: e4. PMID 19173758 DOI: 10.1017/S1462399409000969 |
0.378 |
|
| 2009 |
Hou Z, Matherly LH. Oligomeric structure of the human reduced folate carrier: identification of homo-oligomers and dominant-negative effects on carrier expression and function. The Journal of Biological Chemistry. 284: 3285-93. PMID 19019821 DOI: 10.1074/Jbc.M807206200 |
0.398 |
|
| 2009 |
Xie C, Edwards H, Polin L, Zhou H, Wang X, Yang S, LoGrasso SB, Buck S, Stout M, Rubnitz J, Matherly L, Taub J, Yu Q, Ge Y. Synergistic Antileukemic Interactions Between Valproic Acid and Cytarabine: A Potential Means to Improve the Treatment of Pediatric Acute Myeloid Leukemia. Blood. 114: 2084-2084. DOI: 10.1182/Blood.V114.22.2084.2084 |
0.371 |
|
| 2009 |
Edwards H, Xie C, Dombkowski A, Keller M, Stout M, Buck S, Matherly L, Taub J, Ge Y. Overexpression of GATA1 Confers Chemotherapy Resistance in Pediatric Acute Megakaryocytic Leukemia. Blood. 114: 2039-2039. DOI: 10.1182/Blood.V114.22.2039.2039 |
0.395 |
|
| 2008 |
Matherly LH, Hou Z. Structure and function of the reduced folate carrier a paradigm of a major facilitator superfamily mammalian nutrient transporter. Vitamins and Hormones. 79: 145-84. PMID 18804694 DOI: 10.1016/S0083-6729(08)00405-6 |
0.378 |
|
| 2008 |
Deng Y, Wang Y, Cherian C, Hou Z, Buck SA, Matherly LH, Gangjee A. Synthesis and discovery of high affinity folate receptor-specific glycinamide ribonucleotide formyltransferase inhibitors with antitumor activity. Journal of Medicinal Chemistry. 51: 5052-63. PMID 18680275 DOI: 10.1021/Jm8003366 |
0.438 |
|
| 2008 |
Lafiura KM, Edwards H, Taub JW, Matherly LH, Fontana JA, Mohamed AN, Ravindranath Y, Ge Y. Identification and characterization of novel AML1-ETO fusion transcripts in pediatric t(8;21) acute myeloid leukemia: A report from the Children's Oncology Group Oncogene. 27: 4933-4942. PMID 18469864 DOI: 10.1038/Onc.2008.134 |
0.337 |
|
| 2008 |
Deng Y, Hou Z, Wang L, Cherian C, Wu J, Gangjee A, Matherly LH. Role of lysine 411 in substrate carboxyl group binding to the human reduced folate carrier, as determined by site-directed mutagenesis and affinity inhibition. Molecular Pharmacology. 73: 1274-81. PMID 18182479 DOI: 10.1124/Mol.107.043190 |
0.395 |
|
| 2008 |
Ge Y, LaFiura KM, Dombkowski AA, Chen Q, Payton SG, Buck SA, Salagrama S, Diakiw AE, Matherly LH, Taub JW. The role of the proto-oncogene ETS2 in acute megakaryocytic leukemia biology and therapy. Leukemia. 22: 521-9. PMID 18094719 DOI: 10.1038/Sj.Leu.2405066 |
0.595 |
|
| 2008 |
Patterson D, Graham C, Cherian C, Matherly LH. A humanized mouse model for the reduced folate carrier. Molecular Genetics and Metabolism. 93: 95-103. PMID 17983788 DOI: 10.1016/J.Ymgme.2007.09.014 |
0.377 |
|
| 2008 |
Chen Q, Gedman AL, Matherly LH, Taub JW. Analysis of Clonal T-Cell Receptor Gamma Gene Rearrangements, NOTCH1, FBW7 and PTEN Mutations in Paired Pediatric T-Cell Acute Lymphoblastic Leukemia Samples at Diagnosis and Relapse Reveals Evidence of Relapse in New Leukemic Clones. Blood. 112: 1488-1488. DOI: 10.1182/Blood.V112.11.1488.1488 |
0.335 |
|
| 2007 |
Qiu A, Min SH, Jansen M, Malhotra U, Tsai E, Cabelof DC, Matherly LH, Zhao R, Akabas MH, Goldman ID. Rodent intestinal folate transporters (SLC46A1): secondary structure, functional properties, and response to dietary folate restriction. American Journal of Physiology. Cell Physiology. 293: C1669-78. PMID 17898134 DOI: 10.1152/Ajpcell.00202.2007 |
0.388 |
|
| 2007 |
Lash LH, Putt DA, Xu F, Matherly LH. Role of rat organic anion transporter 3 (Oat3) in the renal basolateral transport of glutathione. Chemico-Biological Interactions. 170: 124-34. PMID 17719021 DOI: 10.1016/J.Cbi.2007.07.004 |
0.36 |
|
| 2007 |
Matherly LH, Hou Z, Deng Y. Human reduced folate carrier: translation of basic biology to cancer etiology and therapy. Cancer Metastasis Reviews. 26: 111-28. PMID 17334909 DOI: 10.1007/S10555-007-9046-2 |
0.451 |
|
| 2007 |
Payton SG, Haska CL, Flatley RM, Ge Y, Matherly LH. Effects of 5' untranslated region diversity on the posttranscriptional regulation of the human reduced folate carrier. Biochimica Et Biophysica Acta. 1769: 131-8. PMID 17306382 DOI: 10.1016/J.Bbaexp.2006.12.006 |
0.611 |
|
| 2007 |
Ge Y, Haska CL, LaFiura K, Devidas M, Linda SB, Liu M, Thomas R, Taub JW, Matherly LH. Prognostic role of the reduced folate carrier, the major membrane transporter for methotrexate, in childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 451-7. PMID 17255265 DOI: 10.1158/1078-0432.Ccr-06-2145 |
0.348 |
|
| 2007 |
Lash LH, Putt DA, Xu F, Matherly LH. Role of organic anion transporter 3 (Oat3) in the renal transport of glutathione (GSH) The Faseb Journal. 21. DOI: 10.1096/Fasebj.21.5.A438 |
0.302 |
|
| 2006 |
Hou Z, Ye J, Haska CL, Matherly LH. Transmembrane domains 4, 5, 7, 8, and 10 of the human reduced folate carrier are important structural or functional components of the transmembrane channel for folate substrates. The Journal of Biological Chemistry. 281: 33588-96. PMID 16923800 DOI: 10.1074/Jbc.M607049200 |
0.395 |
|
| 2006 |
Gurdag S, Khandare J, Stapels S, Matherly LH, Kannan RM. Activity of dendrimer-methotrexate conjugates on methotrexate-sensitive and -resistant cell lines. Bioconjugate Chemistry. 17: 275-83. PMID 16536456 DOI: 10.1021/Bc0501855 |
0.367 |
|
| 2006 |
Yang LV, Wan J, Ge Y, Fu Z, Kim SY, Fujiwara Y, Taub JW, Matherly LH, Eliason J, Li L. The GATA site-dependent hemogen promoter is transcriptionally regulated by GATA1 in hematopoietic and leukemia cells Leukemia. 20: 417-425. PMID 16437149 DOI: 10.1038/Sj.Leu.2404105 |
0.395 |
|
| 2006 |
Liu M, Ge Y, Payton SG, Aboukameel A, Buck S, Flatley RM, Haska C, Mohammad R, Taub JW, Matherly LH. Transcriptional regulation of the human reduced folate carrier in childhood acute lymphoblastic leukemia cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 608-16. PMID 16428507 DOI: 10.1158/1078-0432.Ccr-05-1954 |
0.581 |
|
| 2006 |
Xu F, Putt DA, Matherly LH, Lash LH. Modulation of expression of rat mitochondrial 2-oxoglutarate carrier in NRK-52E cells alters mitochondrial transport and accumulation of glutathione and susceptibility to chemically induced apoptosis. The Journal of Pharmacology and Experimental Therapeutics. 316: 1175-86. PMID 16291728 DOI: 10.1124/Jpet.105.094599 |
0.353 |
|
| 2006 |
Ge Y, Dombkowski AA, LaFiura KM, Tatman D, Yedidi RS, Stout ML, Buck SA, Massey G, Becton DL, Weinstein HJ, Ravindranath Y, Matherly LH, Taub JW. Differential gene expression, GATA1 target genes, and the chemotherapy sensitivity of Down syndrome megakaryocytic leukemia. Blood. 107: 1570-81. PMID 16249385 DOI: 10.1182/Blood-2005-06-2219 |
0.367 |
|
| 2005 |
Payton SG, Liu M, Ge Y, Matherly LH. Transcriptional regulation of the human reduced folate carrier A1/A2 promoter: Identification of critical roles for the USF and GATA families of transcription factors. Biochimica Et Biophysica Acta. 1731: 115-24. PMID 16225938 DOI: 10.1016/J.Bbaexp.2005.08.010 |
0.583 |
|
| 2005 |
Hou Z, Stapels SE, Haska CL, Matherly LH. Localization of a substrate binding domain of the human reduced folate carrier to transmembrane domain 11 by radioaffinity labeling and cysteine-substituted accessibility methods. The Journal of Biological Chemistry. 280: 36206-13. PMID 16115875 DOI: 10.1074/Jbc.M507295200 |
0.402 |
|
| 2005 |
Ge Y, Stout ML, Tatman DA, Jensen TL, Buck S, Thomas RL, Ravindranath Y, Matherly LH, Taub JW. GATA1, cytidine deaminase, and the high cure rate of Down syndrome children with acute megakaryocytic leukemia. Journal of the National Cancer Institute. 97: 226-31. PMID 15687366 DOI: 10.1093/Jnci/Dji026 |
0.322 |
|
| 2005 |
Payton SG, Whetstine JR, Ge Y, Matherly LH. Transcriptional regulation of the human reduced folate carrier promoter C: synergistic transactivation by Sp1 and C/EBP beta and identification of a downstream repressor. Biochimica Et Biophysica Acta. 1727: 45-57. PMID 15652157 DOI: 10.1016/J.Bbaexp.2004.11.006 |
0.728 |
|
| 2005 |
Liu M, Ge Y, Cabelof DC, Aboukameel A, Heydari AR, Mohammad R, Matherly LH. Structure and regulation of the murine reduced folate carrier gene: identification of four noncoding exons and promoters and regulation by dietary folates. The Journal of Biological Chemistry. 280: 5588-97. PMID 15579899 DOI: 10.1074/Jbc.M412662200 |
0.357 |
|
| 2004 |
Witt TL, Stapels SE, Matherly LH. Restoration of transport activity by co-expression of human reduced folate carrier half-molecules in transport-impaired K562 cells: localization of a substrate binding domain to transmembrane domains 7-12. The Journal of Biological Chemistry. 279: 46755-63. PMID 15337749 DOI: 10.1074/Jbc.M408696200 |
0.397 |
|
| 2004 |
Flatley RM, Payton SG, Taub JW, Matherly LH. Primary acute lymphoblastic leukemia cells use a novel promoter and 5'noncoding exon for the human reduced folate carrier that encodes a modified carrier translated from an upstream translational start. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 5111-22. PMID 15297414 DOI: 10.1158/1078-0432.Ccr-04-0116 |
0.557 |
|
| 2004 |
Liu M, Whetstine JR, Payton SG, Ge Y, Flatley RM, Matherly LH. Roles of USF, Ikaros and Sp proteins in the transcriptional regulation of the human reduced folate carrier B promoter. The Biochemical Journal. 383: 249-57. PMID 15214842 DOI: 10.1042/Bj20040414 |
0.739 |
|
| 2004 |
Kaufman Y, Drori S, Cole PD, Kamen BA, Sirota J, Ifergan I, Arush MW, Elhasid R, Sahar D, Kaspers GJ, Jansen G, Matherly LH, Rechavi G, Toren A, Assaraf YG. Reduced folate carrier mutations are not the mechanism underlying methotrexate resistance in childhood acute lymphoblastic leukemia. Cancer. 100: 773-82. PMID 14770434 DOI: 10.1002/Cncr.20018 |
0.326 |
|
| 2004 |
Ge Y, Jensen TL, Stout ML, Flatley RM, Grohar PJ, Ravindranath Y, Matherly LH, Taub JW. The role of cytidine deaminase and GATA1 mutations in the increased cytosine arabinoside sensitivity of Down syndrome myeloblasts and leukemia cell lines. Cancer Research. 64: 728-35. PMID 14744791 DOI: 10.1158/0008-5472.Can-03-2456 |
0.4 |
|
| 2004 |
Cao W, Matherly LH. Analysis of the membrane topology for transmembrane domains 7-12 of the human reduced folate carrier by scanning cysteine accessibility methods. The Biochemical Journal. 378: 201-6. PMID 14602046 DOI: 10.1042/Bj20031288 |
0.339 |
|
| 2004 |
Matherly LH. Human reduced folate carrier gene and transcript variants: Functional, physiologic, and pharmacologic consequences Current Pharmacogenomics. 2: 287-298. DOI: 10.2174/1570160043377547 |
0.336 |
|
| 2003 |
Ge Y, Jensen TL, Matherly LH, Taub JW. Physical and functional interactions between USF and Sp1 proteins regulate human deoxycytidine kinase promoter activity. The Journal of Biological Chemistry. 278: 49901-10. PMID 14514691 DOI: 10.1074/Jbc.M305085200 |
0.327 |
|
| 2003 |
Li M, Zhou JY, Ge Y, Matherly LH, Wu GS. The phosphatase MKP1 is a transcriptional target of p53 involved in cell cycle regulation. The Journal of Biological Chemistry. 278: 41059-68. PMID 12890671 DOI: 10.1074/Jbc.M307149200 |
0.354 |
|
| 2003 |
Matherly LH, Goldman DI. Membrane transport of folates. Vitamins and Hormones. 66: 403-56. PMID 12852262 DOI: 10.1016/S0083-6729(03)01012-4 |
0.404 |
|
| 2003 |
Cao W, Matherly LH. Characterization of a cysteine-less human reduced folate carrier: localization of a substrate-binding domain by cysteine-scanning mutagenesis and cysteine accessibility methods. The Biochemical Journal. 374: 27-36. PMID 12749765 DOI: 10.1042/Bj20030301 |
0.42 |
|
| 2003 |
Ge Y, Jensen TL, Matherly LH, Taub JW. Transcriptional regulation of the cystathionine-beta -synthase gene in Down syndrome and non-Down syndrome megakaryocytic leukemia cell lines. Blood. 101: 1551-7. PMID 12393509 DOI: 10.1182/Blood-2002-07-2337 |
0.383 |
|
| 2003 |
Liu XY, Witt TL, Matherly LH. Restoration of high-level transport activity by human reduced folate carrier/ThTr1 thiamine transporter chimaeras: role of the transmembrane domain 6/7 linker region in reduced folate carrier function. The Biochemical Journal. 369: 31-7. PMID 12227830 DOI: 10.1042/Bj20020419 |
0.391 |
|
| 2002 |
Witt TL, Matherly LH. Identification of lysine-411 in the human reduced folate carrier as an important determinant of substrate selectivity and carrier function by systematic site-directed mutagenesis. Biochimica Et Biophysica Acta. 1567: 56-62. PMID 12488038 DOI: 10.1016/S0005-2736(02)00583-7 |
0.404 |
|
| 2002 |
Gifford AJ, Haber M, Witt TL, Whetstine JR, Taub JW, Matherly LH, Norris MD. Role of the E45K-reduced folate carrier gene mutation in methotrexate resistance in human leukemia cells. Leukemia. 16: 2379-87. PMID 12454742 DOI: 10.1038/Sj.Leu.2402655 |
0.692 |
|
| 2002 |
Ge Y, Jensen TL, Matherly LH, Taub JW. Synergistic regulation of human cystathionine-beta-synthase-1b promoter by transcription factors NF-YA isoforms and Sp1. Biochimica Et Biophysica Acta. 1579: 73-80. PMID 12427542 DOI: 10.1016/S0167-4781(02)00509-2 |
0.332 |
|
| 2002 |
Lash LH, Putt DA, Matherly LH. Protection of NRK-52E cells, a rat renal proximal tubular cell line, from chemical-induced apoptosis by overexpression of a mitochondrial glutathione transporter. The Journal of Pharmacology and Experimental Therapeutics. 303: 476-86. PMID 12388626 DOI: 10.1124/Jpet.102.040220 |
0.368 |
|
| 2002 |
Whetstine JR, Witt TL, Matherly LH. The human reduced folate carrier gene is regulated by the AP2 and sp1 transcription factor families and a functional 61-base pair polymorphism. The Journal of Biological Chemistry. 277: 43873-80. PMID 12228234 DOI: 10.1074/Jbc.M208296200 |
0.666 |
|
| 2002 |
Liu XY, Matherly LH. Analysis of membrane topology of the human reduced folate carrier protein by hemagglutinin epitope insertion and scanning glycosylation insertion mutagenesis. Biochimica Et Biophysica Acta. 1564: 333-42. PMID 12175915 DOI: 10.1016/S0005-2736(02)00467-4 |
0.361 |
|
| 2002 |
Whetstine JR, Flatley RM, Matherly LH. The human reduced folate carrier gene is ubiquitously and differentially expressed in normal human tissues: identification of seven non-coding exons and characterization of a novel promoter. The Biochemical Journal. 367: 629-40. PMID 12144527 DOI: 10.1042/Bj20020512 |
0.677 |
|
| 2002 |
Adachi M, Sampath J, Lan LB, Sun D, Hargrove P, Flatley R, Tatum A, Edwards MZ, Wezeman M, Matherly L, Drake R, Schuetz J. Expression of MRP4 confers resistance to ganciclovir and compromises bystander cell killing. The Journal of Biological Chemistry. 277: 38998-9004. PMID 12105214 DOI: 10.1074/Jbc.M203262200 |
0.399 |
|
| 2002 |
Sampath J, Adachi M, Hatse S, Naesens L, Balzarini J, Flatley RM, Matherly LH, Schuetz JD. Role of MRP4 and MRP5 in biology and chemotherapy Aaps Pharmsci. 4. DOI: 10.1208/Ps040314 |
0.401 |
|
| 2001 |
Whetstine JR, Gifford AJ, Witt T, Liu XY, Flatley RM, Norris M, Haber M, Taub JW, Ravindranath Y, Matherly LH. Single nucleotide polymorphisms in the human reduced folate carrier: characterization of a high-frequency G/A variant at position 80 and transport properties of the His(27) and Arg(27) carriers. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 7: 3416-22. PMID 11705857 |
0.639 |
|
| 2001 |
Ge Y, Matherly LH, Taub JW. Transcriptional Regulation of Cell-specific Expression of the Human Cystathionine β-Synthase Gene by Differential Binding of Sp1/Sp3 to the -1b Promoter Journal of Biological Chemistry. 276: 43570-43579. PMID 11562358 DOI: 10.1074/Jbc.M104930200 |
0.328 |
|
| 2001 |
Matherly LH. Molecular and cellular biology of the human reduced folate carrier Progress in Nucleic Acid Research and Molecular Biology. 67: 131-162. PMID 11525381 DOI: 10.1016/S0079-6603(01)67027-2 |
0.415 |
|
| 2001 |
Liu XY, Matherly LH. Functional interactions between arginine-133 and aspartate-88 in the human reduced folate carrier: Evidence for a charge-pair association Biochemical Journal. 358: 511-516. PMID 11513752 DOI: 10.1042/0264-6021:3580511 |
0.388 |
|
| 2001 |
Ge Y, Konrad MA, Matherly LH, Taub JW. Transcriptional regulation of the human cystathionine β-synthase - 1b basal promoter: Synergistic transactivation by transcription factors NF-Y and Sp1/Sp3 Biochemical Journal. 357: 97-105. PMID 11415440 DOI: 10.1042/0264-6021:3570097 |
0.333 |
|
| 2001 |
Shah SJ, Taub JW, Witt TL, Pollock BH, Ding BC, Moore DS, Amylon M, Pullen J, Ravindranath Y, Matherly LH. Relationship of p15 and p16 gene alterations to elevated dihydrofolate reductase in childhood acute lymphoblastic leukaemia. British Journal of Haematology. 113: 746-56. PMID 11380466 DOI: 10.1046/J.1365-2141.2001.02775.X |
0.619 |
|
| 2001 |
Ding BC, Witt TL, Hukku B, Heng H, Zhang L, Matherly LH. Association of deletions and translocation of the reduced folate carrier gene with profound loss of gene expression in methotrexate-resistant K562 human erythroleukemia cells. Biochemical Pharmacology. 61: 665-75. PMID 11266651 DOI: 10.1016/S0006-2952(01)00535-4 |
0.671 |
|
| 2001 |
Ding BC, Whetstine JR, Witt TL, Schuetz JD, Matherly LH. Repression of human reduced folate carrier gene expression by wild type p53. The Journal of Biological Chemistry. 276: 8713-9. PMID 11106643 DOI: 10.1074/Jbc.M005248200 |
0.761 |
|
| 2001 |
Whetstine JR, Matherly LH. The basal promoters for the human reduced folate carrier gene are regulated by a GC-box and a cAMP-response element/AP-1-like element: Basis for tissue-specific gene expression Journal of Biological Chemistry. 276: 6350-6358. PMID 11078737 DOI: 10.1074/Jbc.M008074200 |
0.679 |
|
| 2000 |
Said HM, Chatterjee N, Ul Haq R, Subramanian VS, Ortiz A, Matherly LH, Sirotnak FM, Halsted C, Rubin SA. Adaptive regulation of intestinal folate uptake: Effect of dietary folate deficiency American Journal of Physiology - Cell Physiology. 279. PMID 11078704 DOI: 10.1152/Ajpcell.2000.279.6.C1889 |
0.324 |
|
| 1999 |
Matherly LH, Taub JW. Molecular and cellular correlates of methotrexate response in childhood acute lymphoblastic leukemia Leukemia and Lymphoma. 35: 1-20. PMID 10512159 DOI: 10.3109/10428199909145701 |
0.301 |
|
| 1999 |
Taub JW, Huang X, Matherly LH, Stout ML, Buck SA, Massey GV, Becton DL, Chang MN, Weinstein HJ, Ravindranath Y. Expression of chromosome 21-localized genes in acute myeloid leukemia: Differences between Down syndrome and non-Down syndrome blast cells and relationship to in vitro sensitivity to cytosine arabinoside and daunorubicin Blood. 94: 1393-1400. PMID 10438727 DOI: 10.1182/Blood.V94.4.1393.416K32_1393_1400 |
0.356 |
|
| 1998 |
Zhang L, Wong SC, Matherly LH. Structure and organization of the human reduced folate carrier gene Biochimica Et Biophysica Acta - Gene Structure and Expression. 1442: 389-393. PMID 9804996 DOI: 10.1016/S0167-4781(98)00168-7 |
0.342 |
|
| 1998 |
Wong SC, Zhang L, Proefke SA, Matherly LH. Effects of the loss of capacity for N-glycosylation on the transport activity and cellular localization of the human reduced folate carrier Biochimica Et Biophysica Acta - Biomembranes. 1375: 6-12. PMID 9767079 DOI: 10.1016/S0005-2736(98)00118-7 |
0.426 |
|
| 1998 |
Gifford AJ, Kavallaris M, Madafiglio J, Matherly LH, Stewart BW, Haber M, Norris MD. P-glycoprotein-mediated methotrexate resistance in CCRF-CEM sublines deficient in methotrexate accumulation due to a point mutation in the reduced folate carrier gene. International Journal of Cancer. Journal International Du Cancer. 78: 176-81. PMID 9754649 DOI: 10.1002/(Sici)1097-0215(19981005)78:2<176::Aid-Ijc10>3.0.Co;2-9 |
0.393 |
|
| 1998 |
Zhang L, Wong SC, Matherly LH. Transcript heterogeneity of the human reduced folate carrier results from the use of multiple promoters and variable splicing of alternative upstream exons Biochemical Journal. 332: 773-780. PMID 9620882 DOI: 10.1042/Bj3320773 |
0.354 |
|
| 1998 |
Wong SC, Zhang L, Proefke SA, Hukku B, Matherly LH. Gene amplification and increased expression of the reduced folate carrier in transport elevated K562 cells Biochemical Pharmacology. 55: 1135-1138. PMID 9605439 DOI: 10.1016/S0006-2952(97)00639-4 |
0.344 |
|
| 1997 |
Matherly LH, Taub JW, Wong SC, Simpson PM, Ekizian R, Buck S, Williamson M, Amylon M, Pullen J, Camitta B, Ravindranath Y. Increased frequency of expression of elevated dihydrofolate reductasc in T-cell versus B-precursor acute lymphoblastic leukemia in children Blood. 90: 578-589. PMID 9226157 DOI: 10.1182/Blood.V90.2.578.578_578_589 |
0.35 |
|
| 1997 |
Wong SC, McQuade R, Proefke SA, Bhushan A, Matherly LH. Human K562 transfectants expressing high levels of reduced folate carrier but exhibiting low transport activity Biochemical Pharmacology. 53: 199-206. PMID 9037252 DOI: 10.1016/S0006-2952(96)00710-1 |
0.407 |
|
| 1996 |
Matherly LH, Taub JW. Methotrexate pharmacology and resistance in childhood acute lymphoblastic leukemia Leukemia and Lymphoma. 21: 359-368. PMID 9172800 DOI: 10.3109/10428199609093433 |
0.333 |
|
| 1995 |
Wong SC, Proefke SA, Bhushan A, Matherly LH. Isolation of human cDNAs that restore methotrexate sensitivity and reduced folate carrier activity in methotrexate transport-defective Chinese hamster ovary cell Journal of Biological Chemistry. 270: 17468-17475. PMID 7615551 DOI: 10.1074/Jbc.270.29.17468 |
0.415 |
|
| 1994 |
Matherly LH, Angeles SM. Role of N-glycosylation in the structure and function of the methotrexate membrane transporter from CCRF-CEM human lymphoblastic leukemia cells Biochemical Pharmacology. 47: 1094-1098. PMID 8147910 DOI: 10.1016/0006-2952(94)90423-5 |
0.364 |
|
| 1993 |
Matherly LH, Angeles SM. Determinants of the disparate antitumor effects of (6R)5,10-dideaza- 5,6,7,8-tetrahydrofolate and methotrexate toward methotrexate resistant CCRF- CEM cells, characterized by severely impaired antifolate membrane transport Advances in Experimental Medicine and Biology. 338: 783-786. PMID 8304229 DOI: 10.1007/978-1-4615-2960-6_164 |
0.388 |
|
| 1993 |
Matherly LH, Angeles SM, McGuire JJ. Determinants of the disparate antitumor activities of (6R)-5,10-dideaza-5,6,7,8-tetrahydrofolate and methotrexate toward human lymphoblastic leukemia cells, characterized by severely impaired antifolate membrane transport Biochemical Pharmacology. 46: 2185-2195. PMID 7506026 DOI: 10.1016/0006-2952(93)90608-Y |
0.428 |
|
| 1991 |
Kavallaris M, Haber M, Norris MD, Matherly LH, Stewart BW. Characterization of Mechanisms Mediating Drug Resistance in Human Leukemic Cells Selected with High Concentration Methotrexate Pteridines. 3: 119-121. DOI: 10.1515/Pteridines.1991.3.12.119 |
0.31 |
|
| 1990 |
Matherly LH, Muench SP. Evidence for a localized conversion of endogenous tetrahydrofolate cofactors to dihydrofolate as an important element in antifolate action in murine leukemia cells Biochemical Pharmacology. 39: 2005-2014. PMID 2141258 DOI: 10.1016/0006-2952(90)90622-R |
0.36 |
|
| 1989 |
Matherly LH, Schuetz JD, Westin E, Goldman ID. A method for the synchronization of cultured cells with aphidicolin: Application to the large-scale synchronization of L1210 cells and the study of the cell cycle regulation of thymidylate synthase and dihydrofolate reductase Analytical Biochemistry. 182: 338-345. PMID 2514611 DOI: 10.1016/0003-2697(89)90605-2 |
0.348 |
|
| 1983 |
Matherly LH, Phillips AT. Identification of the enol tautomer of imidazolone propionate as the urocanase reaction product Archives of Biochemistry and Biophysics. 220: 314-317. PMID 6131645 DOI: 10.1016/0003-9861(83)90416-2 |
0.585 |
|
| 1982 |
Matherly LH, Johnson KA, Phillips AT. Transient-state kinetic analysis of urocanase Biochemistry. 21: 2795-2798. PMID 6124274 DOI: 10.1021/Bi00540A034 |
0.597 |
|
| 1982 |
Matherly LH, DeBrosse CW, Phillips AT. A covalent nicotinamide adenine dinucleotide intermediate in the urocanase reaction Biochemistry. 21: 2789-2794. PMID 6124273 DOI: 10.1021/Bi00540A033 |
0.64 |
|
| 1981 |
Egan RM, Matherly LH, Phillips AT. Mechanism of urocanase as studied by deuterium isotope effects and labeling patterns Biochemistry. 20: 132-137. PMID 6110440 DOI: 10.1021/Bi00504A022 |
0.599 |
|
| 1980 |
Matherly LH, Phillips AT. Substrate-mediated inactivation of urocanase from Pseudomonas putida. Evidence for an essential sulfhydryl group Biochemistry. 19: 5814-5818. PMID 6109547 DOI: 10.1021/Bi00566A024 |
0.634 |
|
| Show low-probability matches. |
